The Injection Era Is Over
For the past three years, GLP-1 medications have reshaped how we think about weight loss. Semaglutide and tirzepatide produced results that no diet pill had ever come close to delivering. But they all required weekly injections. For a lot of men, that was the dealbreaker.
Not a fear-of-needles thing, necessarily. More of a logistics thing. Keeping a medication refrigerated. Remembering your injection day. Traveling with syringes. Explaining to your wife why there are vials in the butter compartment. It was enough friction to keep millions of men who would have benefited from these drugs from ever starting.
That barrier is now gone. As of mid-2026, two FDA-approved oral GLP-1 pills are available for weight loss. The Wegovy pill (oral semaglutide) launched in January 2026. Foundayo (orforglipron), made by Eli Lilly, followed in April. Both are daily pills. Both start at $149 per month out of pocket. And both represent a genuine inflection point for men dealing with stubborn weight that will not respond to diet and exercise alone.
Here is everything you need to know about each one, how they compare, what they cost, and why men taking these medications should also be paying attention to their testosterone levels.
Oral Wegovy: The First GLP-1 Pill for Weight Loss
Novo Nordisk's oral Wegovy received FDA approval on December 22, 2025, making it the first oral GLP-1 medication approved specifically for weight management. It launched in pharmacies and through telehealth providers in early January 2026.
Oral Wegovy contains the same active ingredient as injectable Wegovy: semaglutide. The difference is the delivery method. Instead of a weekly subcutaneous injection, you take a 25 mg tablet once daily.
How It Works
Semaglutide mimics a natural hormone called GLP-1 (glucagon-like peptide-1) that your body releases after eating. It signals to your brain that you are full, slows gastric emptying so food stays in your stomach longer, and reduces the appetite signals that drive overeating. The result is that you eat less without feeling like you are constantly fighting hunger.
The oral formulation uses a permeation enhancer called SNAC (sodium N-[8-(2-hydroxybenzoyl) amino caprylate]) that helps the semaglutide molecule survive your stomach acid and absorb through the stomach lining. This is why the oral dose is 25 mg compared to 2.4 mg for the injection. Most of the oral dose is broken down before it reaches your bloodstream. Only a small fraction gets absorbed, but it is enough to produce comparable weight loss.
The Clinical Data
The approval was based on the OASIS-4 trial, which studied 307 adults with obesity or overweight with at least one comorbid condition. Over 64 weeks, participants taking oral Wegovy 25 mg daily lost an average of 16.6% of their body weight when treatment was adhered to, compared to 2.7% in the placebo group. When including participants who discontinued treatment, the average was 13.6% versus 2.2%.
For context, that is remarkably close to the results seen with injectable Wegovy in the landmark STEP-1 trial (16.9% weight loss at 68 weeks). A daily pill producing comparable weight loss to a weekly injection is a significant achievement.
Oral Wegovy must be taken on an empty stomach with no more than 4 ounces of plain water, and you need to wait at least 30 minutes before eating, drinking, or taking other medications. This fasting window is necessary for proper absorption. For men with unpredictable morning routines, this can be a real constraint.
Oral Wegovy is also approved for a second indication: reducing the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with established cardiovascular disease and overweight or obesity. This dual approval makes it particularly relevant for men over 40 who carry cardiovascular risk alongside excess weight.
Foundayo (Orforglipron): Lilly's No-Restrictions Pill
Three months after oral Wegovy launched, Eli Lilly brought Foundayo (orforglipron) to market. The FDA approved Foundayo on April 1, 2026, and it became the fastest new molecular entity approval since 2002, cleared in just 50 days under the Commissioner's National Priority Voucher program. It was available for prescriptions immediately, with shipping through LillyDirect starting April 6.
What Makes Foundayo Different
Foundayo is not semaglutide in a different package. It is an entirely different molecule. Unlike semaglutide, which is a peptide (a modified version of a naturally occurring hormone), orforglipron is a small molecule. Think of the difference between a biological drug and a traditional chemical drug. This distinction has practical consequences.
Because orforglipron is a small molecule, it does not require the SNAC absorption enhancer that oral semaglutide depends on. That means:
- No fasting requirement. You can take Foundayo with or without food.
- No water restriction. Drink whatever you want.
- Any time of day. Morning, afternoon, evening. Your choice.
- No 30-minute wait. Take it and go about your day.
For men who travel frequently, have irregular schedules, or simply do not want to restructure their morning around a pill, this flexibility is a meaningful advantage.
The Clinical Data
Foundayo's approval was based on the ATTAIN-1 trial. Over 72 weeks, participants on the highest dose (36 mg, which is now marketed as 17.2 mg in the approved dosing) lost an average of 12.4% of their body weight when they stayed on treatment, compared to 0.9% with placebo. That translates to an average of 27.3 pounds lost.
Beyond weight loss, Foundayo also produced reductions in waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure across all doses. These are cardiometabolic markers that matter for men over 35, especially those with metabolic syndrome or insulin resistance.
Lilly also studied what happens when patients switch from injectable GLP-1s to Foundayo. People who transitioned from injectable Wegovy regained an average of just 2 pounds, while those who switched from Zepbound (tirzepatide) regained about 11 pounds. This suggests Foundayo can serve as a maintenance option for men who have already lost weight on an injectable and want to stop injecting.
Oral Wegovy vs. Foundayo: Head-to-Head Comparison
Both pills work through the same mechanism (GLP-1 receptor agonism), but they differ in important practical ways. Here is how they stack up:
| Feature | Oral Wegovy | Foundayo |
|---|---|---|
| Active ingredient | Semaglutide (peptide) | Orforglipron (small molecule) |
| Manufacturer | Novo Nordisk | Eli Lilly |
| FDA approved | December 2025 | April 2026 |
| Dosing | Once daily | Once daily |
| Food restrictions | Must take fasting, wait 30 min | None — any time, with or without food |
| Avg. weight loss | ~16.6% (OASIS-4, 64 weeks) | ~12.4% (ATTAIN-1, 72 weeks) |
| CV risk indication | Yes (approved) | Not yet |
| Starting self-pay cost | $149/month | $149/month |
| Maintenance dose cost | ~$299/month | $299–$349/month |
| Insurance copay | As low as $25/month | As low as $25/month |
The weight loss numbers favor oral Wegovy, but there are nuances. The trials used different durations (64 vs. 72 weeks), different populations, and different dose titration schedules. Head-to-head trials comparing the two directly have not yet been completed. Still, the data suggests that semaglutide-based products tend to produce slightly more weight loss than orforglipron at their respective maximum doses.
Where Foundayo wins is convenience. No fasting, no water restrictions, no 30-minute wait. If compliance is the bottleneck, and for most people it is, the easier pill to take consistently may ultimately produce better real-world results regardless of what the clinical trial numbers say.
What Oral GLP-1s Mean for Men's Health
Most GLP-1 coverage focuses on weight loss as the headline number. But for men, particularly men over 35, the downstream effects of significant weight loss on hormonal health are where the real story gets interesting.
Weight Loss Can Raise Your Testosterone
Excess body fat, especially visceral fat around the midsection, is one of the most potent suppressors of testosterone production in men. Fat tissue contains aromatase, an enzyme that converts testosterone to estrogen. The more fat you carry, the more testosterone you lose to conversion, and the higher your estradiol levels climb.
This creates a vicious cycle: low testosterone promotes fat storage, and more fat further suppresses testosterone. Researchers call this functional hypogonadism, meaning your testosterone is low not because of a problem with your testes or pituitary, but because excess weight is dragging your levels down.
The good news: losing weight can break the cycle. A meta-analysis found that diet-associated weight loss of approximately 10% increased testosterone by an average of 84 ng/dL. Surgical weight loss of around 32% increased testosterone by 251 ng/dL. The pattern is clear: the more weight you lose, the more your testosterone recovers.
If you are carrying 30 to 50 extra pounds and your testosterone is in the 250–400 ng/dL range, losing 12 to 17% of your body weight on an oral GLP-1 could meaningfully improve your levels. Some men may find that weight loss alone resolves their hormonal imbalance symptoms. Others may still need testosterone therapy if their baseline was already clinically low.
Insulin Resistance and the Testosterone Connection
GLP-1 medications do more than just reduce appetite. They improve insulin sensitivity, lower fasting glucose, and reduce HbA1c. This matters because insulin resistance is independently associated with lower testosterone levels in men. By improving metabolic function, GLP-1 therapy may indirectly support healthier testosterone production even beyond what the weight loss alone would achieve. (Read more about the testosterone-diabetes connection.)
The Muscle Loss Question — and How to Address It
Here is the part of the oral GLP-1 conversation that does not get enough attention, especially for men: muscle loss.
When you lose a significant amount of weight on any intervention, whether it is diet, surgery, or a GLP-1 medication, some of that weight loss comes from lean body mass, including muscle. This is basic physiology. Your body is in a caloric deficit, and while most of the weight it sheds is fat, muscle is not entirely spared.
DEXA sub-analyses from the STEP-1 trial with injectable semaglutide showed that approximately 30 to 40% of total weight loss was attributable to lean mass. For a man who loses 40 pounds, that means roughly 12 to 16 pounds of it may be muscle.
For a 28-year-old who has never lifted a weight, this may not be clinically significant. For a 45-year-old man who is already fighting age-related muscle loss (sarcopenia), losing another 12 pounds of muscle on top of a natural annual decline can have real consequences: reduced strength, lower metabolic rate, decreased functional capacity, and increased injury risk.
What You Can Do About It
The research is clear that muscle loss during GLP-1 therapy is not inevitable. It is modifiable. Three strategies have the strongest evidence:
- Resistance training. This is non-negotiable. Men on GLP-1 medications should be lifting weights at least three times per week. Progressive resistance training is the single most effective intervention for preserving and building muscle during weight loss.
- Adequate protein intake. Aim for at least 1 gram of protein per pound of target body weight daily. Since GLP-1 medications reduce appetite, it can be challenging to hit protein targets. Prioritize protein at every meal and consider supplementation if needed. (See our GLP-1 diet guide for men.)
- Optimize your testosterone. Testosterone is the primary anabolic hormone in men. It drives muscle protein synthesis, enhances nitrogen retention, and promotes lean mass preservation. If your testosterone is low while you are losing weight on a GLP-1, you are fighting the muscle loss battle with one hand tied behind your back. A 2026 review in Nutrients concluded that while no randomized trials have yet directly studied TRT plus GLP-1 therapy, the physiological rationale for combining them in hypogonadal men is "biologically plausible and clinically relevant."
If you are a man over 35 starting an oral GLP-1, get your bloodwork done before or shortly after you begin. If your testosterone is low, addressing it with TRT alongside your GLP-1 could help you lose fat while preserving the muscle mass you have worked to build.
Side Effects Men Should Know About
The side effect profiles for both oral GLP-1 pills are consistent with what we have seen from injectable versions. The most common side effects are gastrointestinal:
- Nausea — the most frequently reported side effect, affecting roughly 20 to 30% of patients. Typically worst during dose titration and improves over 4 to 8 weeks.
- Diarrhea and constipation — often alternating. GLP-1 slows gastric motility, which can shift bowel patterns in either direction.
- Vomiting — less common than nausea but possible, especially if you eat large meals early in treatment.
- Acid reflux (GERD) — delayed gastric emptying can worsen reflux symptoms.
- Headache and fatigue — reported in both trials, generally mild and transient.
Foundayo's label also notes hair loss as a potential side effect. Hair shedding (telogen effluvium) associated with rapid weight loss is a known phenomenon that is not unique to GLP-1 drugs. It typically occurs 3 to 6 months after significant weight loss begins and is usually temporary. (Learn about the testosterone-hair loss connection.)
Serious Risks to Discuss with Your Doctor
Both medications carry a boxed warning for thyroid C-cell tumors based on animal studies. While this risk has not been confirmed in humans, people with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 should not take either medication.
Other serious but rare risks include pancreatitis, gallbladder disease (particularly gallstones during rapid weight loss), and in the case of Foundayo, a warning that oral contraceptive pills may be less effective during treatment.
Cost and Access in 2026
One of the biggest shifts in the GLP-1 landscape is pricing. When injectable Wegovy launched in 2021, the list price was over $1,300 per month. Most men without premium insurance coverage simply could not afford it. The oral pills have changed the math:
| Medication | Starting Dose (Self-Pay) | Maintenance Dose (Self-Pay) | With Commercial Insurance |
|---|---|---|---|
| Oral Wegovy | $149/month | ~$299/month | As low as $25/month |
| Foundayo | $149/month (0.8 mg) | $299–$349/month | As low as $25/month |
| Injectable Wegovy | $199/month (via GoodRx) | $349/month | Varies widely |
| Zepbound (tirzepatide) | $299/month (via LillyDirect) | $449/month | As low as $25/month |
Starting in July 2026, eligible Medicare Part D beneficiaries can access Foundayo for as low as $50 per month. This is significant for men over 65 who were previously locked out of GLP-1 access due to cost.
Where to Get Them
Both medications are available through:
- Primary care physicians and endocrinologists who can write prescriptions filled at retail pharmacies
- Telehealth platforms including services that specialize in weight management
- LillyDirect (for Foundayo) with free home delivery
- Walgreens, CVS, and other major pharmacies
Availability of compounded versions of oral semaglutide remains limited, as the oral formulation's SNAC technology is difficult to replicate in compounding pharmacies. Foundayo, being a small molecule, may eventually see generic competition, but not for years.
What Is Coming Next
The oral GLP-1 landscape is evolving fast. Several developments expected in late 2026 and 2027 will further expand options for men:
Higher-Dose Injectable Wegovy (7.2 mg)
Novo Nordisk has submitted a higher-dose injectable Wegovy for FDA approval. The 7.2 mg weekly injection produced even greater weight loss than the current 2.4 mg dose. An FDA decision was expected in Q1 2026 and may arrive soon.
CagriSema
Novo Nordisk's CagriSema combines semaglutide with cagrilintide, an amylin analog. Early data suggests weight loss of up to 20 to 25% of body weight, potentially exceeding tirzepatide. An FDA decision is expected by December 2026. If approved, it would be an injectable, but an oral version could follow.
Oral Ozempic for Diabetes
In February 2026, the FDA approved new oral semaglutide tablet formulations (1.5 mg, 4 mg, and 9 mg) under the Ozempic brand name for type 2 diabetes. These tablets use improved bioavailability technology. A higher-dose oral semaglutide (25 mg) specifically for diabetes has an FDA decision expected in Q4 2026.
The Bigger Picture
The GLP-1 class is rapidly bifurcating into injectable options for maximum weight loss and oral options for convenience, maintenance, and broader access. For men who need to lose 50+ pounds, an injectable like Wegovy or Zepbound may still be the best starting point. For men who need to lose 20 to 40 pounds, or who want to maintain weight loss achieved with an injectable, the oral pills offer a practical, sustainable path forward.
Who Should Consider an Oral GLP-1?
Oral GLP-1 medications may be a good fit for men who:
- Have a BMI of 30 or higher (obesity), or a BMI of 27+ with at least one weight-related condition such as high blood pressure, high cholesterol, sleep apnea, or type 2 diabetes
- Have tried diet and exercise without achieving or sustaining meaningful weight loss
- Want the benefits of GLP-1 therapy without weekly injections
- Are already on an injectable GLP-1 and want to transition to a pill for maintenance
- Are concerned about the cost of injectable GLP-1s and want a more affordable entry point
Oral GLP-1s are not appropriate for men who:
- Have a personal or family history of medullary thyroid cancer
- Have a history of pancreatitis
- Are already taking another GLP-1 medication (you cannot stack them)
- Are looking for a short-term quick fix. GLP-1 medications work best as part of an ongoing treatment plan that includes diet, exercise, and hormone optimization
The Bottom Line
The arrival of oral GLP-1 pills in 2026 has removed the two biggest barriers to treatment that kept men from accessing these medications: injections and cost. Oral Wegovy delivers semaglutide's proven weight loss in a daily pill, though with some dosing restrictions. Foundayo offers a different molecule with no food or timing restrictions and comparable results.
For men, the conversation should not stop at weight loss. Significant weight reduction on a GLP-1 medication can improve testosterone levels, insulin sensitivity, and cardiovascular markers. But it can also reduce muscle mass if you are not proactive about resistance training, protein intake, and hormone optimization.
If you are considering an oral GLP-1, or you have already started one, checking your hormone levels is one of the smartest moves you can make. Understanding your testosterone, estradiol, SHBG, and metabolic markers before and during treatment gives you and your provider the data to make sure you are losing fat, not muscle, and improving your health across the board.